Home › Compare › SCNLF vs BTI

SCNLF vs BTI: Dividend Comparison 2026

SCNLF yields 1373.63% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCNLF wins by $315919182.74M in total portfolio value
10 years
SCNLF
SCNLF
● Live price
1373.63%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$315919182.78M
Annual income
$276,344,297,604,930.75
Full SCNLF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — SCNLF vs BTI

📍 SCNLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCNLFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCNLF + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SCNLF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCNLF
Annual income on $10K today (after 15% tax)
$116,758.24/yr
After 10yr DRIP, annual income (after tax)
$234,892,652,964,191.12/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, SCNLF beats the other by $234,892,652,961,822.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCNLF + BTI for your $10,000?

SCNLF: 50%BTI: 50%
100% BTI50/50100% SCNLF
Portfolio after 10yr
$157959591.41M
Annual income
$138,172,148,803,858.69/yr
Blended yield
87.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

SCNLF
No analyst data
Altman Z
-12.0
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCNLF buys
0
BTI buys
0
No recent congressional trades found for SCNLF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCNLFBTI
Forward yield1373.63% ✓5.38%
Annual dividend / share$2.00$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3% ✓
Portfolio after 10y$315919182.78M ✓$37.7K
Annual income after 10y$276,344,297,604,930.75 ✓$2,786.64
Total dividends collected$313011682.66M ✓$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: SCNLF vs BTI ($10,000, DRIP)

YearSCNLF PortfolioSCNLF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$148,063$137,362.64$11,299$598.92+$136.8K → SCNLF
2$2,059,200$1,900,773.30$12,794$703.91+$2.05M → SCNLF
3$26,909,187$24,705,842.24$14,518$829.07+$26.89M → SCNLF
4$330,522,388$301,729,558.78$16,513$978.64+$330.51M → SCNLF
5$3,817,312,082$3,463,653,126.46$18,827$1,157.84+$3817.29M → SCNLF
6$41,470,385,979$37,385,862,050.80$21,518$1,373.12+$41470.36M → SCNLF
7$423,953,934,089$379,580,621,092.34$24,657$1,632.46+$423953.91M → SCNLF
8$4,080,240,641,140$3,626,609,931,664.44$28,329$1,945.74+$4080240.61M → SCNLF
9$36,985,873,996,458$32,620,016,510,437.74$32,637$2,325.33+$36985873.96M → SCNLF
10$315,919,182,781,141$276,344,297,604,930.75$37,708$2,786.64+$315919182.74M → SCNLF

SCNLF vs BTI: Complete Analysis 2026

SCNLF — Stock

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Full SCNLF Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this SCNLF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCNLF vs SCHDSCNLF vs JEPISCNLF vs OSCNLF vs KOSCNLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.